China Pharma Holdings, Inc. (CPHI)

NYSEAMERICAN: CPHI · USD

$0.65

+0.02 (+3.0%)· Recorded snapshot

Market cap	27.9M
Revenue (ttm)	3.9M
Net income (ttm)	-4.5M
EPS (ttm)	-$0.23
Shares out	43M
Volume	132,094
Beta	1.05

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 3.9M
Net income (ttm): -4.5M
EPS (ttm): -$0.23
Market cap: 27.9M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	보유

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 13.4P50 20.2P75 35.7

Trailing P/En/a

P25 15.4P50 25.8P75 43.5

ROE-21

P25 -113.8P50 -46.5P75 -0.9

ROIC-10.9

P25 -68.5P50 -27.1P75 1.8

Benchmarks · 1M

All CPHI indicators

Market & fundamental data

Available fields

205

Groups with data

Currency

USD

Showing 205 of 205 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001106644
Company name	China Pharma Holdings, Inc.
Country	China
Country code	US
CUSIP number	16941T401
Earnings date	2026-11-11
Earnings time	amc
Employees	215
Employees change	-9
Employees growth	-4.02%
Enterprise value	$31.7M
Exchange	NYSEAMERICAN
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Industry	Drug Manufacturers - Specialty & Generic
Is primary listing	Yes
Is SPAC	No
ISIN number	US16941T4013
Last 10-K release date	2026-04-01
Last earnings date	2026-08-14
Last refreshed	2026-10-28
Last stock split date	2025-04-15
Last stock split type	Reverse
Market cap	$27.9M
Market cap category	Nano-Cap
Next earnings date	2026-11-11
Options	No
Price	$0.65
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	CPHI
Website	https://www.chinapharmaholdings.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-34.99%
EV/Sales	7.62x
FCF / EV yield	-0.47%
FCF yield	-0.54%
Industry forward P/E	13.86x
Industry P/E	173.47x
P/B ratio	0.71x
P/S ratio	6.66x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	-111.82%
EBITDA margin	-36.81%
Gross margin	11.76%
Operating margin	-111.82%
Pretax margin	-114.33%
Profit margin	-114.33%
Profit per employee	$-20,813
Revenue per employee	$18,205
ROA	-9.36%
ROA (5Y)	-11.18%
ROCE	-11.82%
ROE	-20.99%
ROE (5Y)	-52.24%
ROIC	-10.91%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	6
EPS growth years	3
Gross profit growth 5Y	-13.54%
Net income growth years	1
Revenue growth	-10.97%
Revenue growth (Q)	-7.55%
Revenue growth (QoQ)	-3.58%
Revenue growth 10Y	-13.22%
Revenue growth 3Y	-21.02%
Revenue growth 5Y	-17.28%
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-1,065
Depreciation and amortization	$2.9M
EBIT	$-4.4M
EBITDA	$-1.4M
EPS	$-0.23
FCF per share	$-0.00
Financing cash flow	$-154,013
Free cash flow	$-141,555
Gross profit	$460,174
Investing cash flow	$-78,992
Net borrowing	$-154,013
Net cash flow	$-320,158
Net income	$-4.5M
Operating income	$-4.4M
Revenue	$3.9M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-1.16
Book value per share	$0.89
Debt / equity	0.11
Interest coverage	-44.19
Long-term assets	$42.7M
Long-term liabilities	$847,021
Net cash (debt)	$-3.8M
Net cash / market cap	-14.38%
Net debt / equity	0.1
Piotroski F-Score	2
Property, plant and equipment	$4.4M
Shareholders' equity	$36.2M
Tangible book value	$-2.2M
Tangible book value per share	$-0.05
Total assets	$44.7M
Total cash	$304,874
Total debt	$4.1M
Total liabilities	$8.5M
WACC	8.92%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.13
Current assets	$2M
Current liabilities	$7.7M
Current ratio	0.26
Inventory turnover	2.27
Net working capital	$-2M
Quick ratio	0.07
Working capital	$-5.7M
Working capital turnover	-0.95

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-646.1%
Dividend yield	0%
Shareholder yield	-646.1%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-99.42%
10Y return CAGR	-40.24%
10Y total return	-99.42%
150-day SMA	$0.85
15Y price change	-99.86%
15Y return CAGR	-35.56%
15Y total return	-99.86%
1D price change	3.02%
1M price change	-18.83%
1M total return	-18.83%
1W price change	-15.78%
1W total return	-15.77%
1Y price change	-65.22%
1Y return CAGR	-65.24%
1Y total return	-65.22%
20-day SMA	$0.72
200-day SMA	$0.84
20Y price change	-99.92%
20Y return CAGR	-29.86%
20Y total return	-99.92%
3M price change	-50.4%
3M total return	-50.4%
3Y price change	-88.91%
3Y return CAGR	-51.94%
3Y total return	-88.91%
50-day SMA	$0.77
50-day SMA vs 200-day SMA	50under200
52-week high	$19.19
52-week high date	2026-07-21
52-week low	$0.38
52-week low date	2026-05-12
5Y price change	-99.81%
5Y return CAGR	-71.47%
5Y total return	-99.81%
6M price change	3.72%
6M total return	3.72%
All-time high	$2,602.50
All-time high date	2003-10-28
All-time low	$0.38
All-time low date	2026-05-12
Average true range (ATR)	$0.10
Average volume	4.2M
Beta (1Y)	-0.15
Beta (2Y)	-0.14
Beta (5Y)	1.05
Change from 52-week high	-96.62%
Change from 52-week low	69.98%
Change from all-time high	-99.98%
Change from all-time low	59.8%
Change from open	7.04%
Day's gap	-3.76%
Dollar volume	$85,729
High price	$0.65
Low price	$0.61
Monthly RSI	30.24
Open price	$0.61
Position in 52-week range	100%
Premarket change	0%
Premarket close	$0.63
Premarket price	$0.63
Previous close	$0.63
Price vs 150-day SMA	-28.3%
Price vs 20-day SMA	-15.15%
Price vs 200-day SMA	-27.28%
Price vs 50-day SMA	-21.12%
Relative volume	0.03
RSI	38.54
Sharpe ratio	0.77
Sharpe ratio (3Y)	0.43
Sharpe ratio (5Y)	0.17
Sortino ratio	5.66
Sortino ratio (3Y)	2.42
Sortino ratio (5Y)	0.85
Volume	132.1K
Weekly RSI	42.32
YTD price change	-49.58%
YTD total return	-49.58%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	3.3M
Float percentage	7.67%
Shares change (QoQ)	58.28%
Shares change (YoY)	646.1%
Shares held by insiders	92.33%
Shares held by institutions	0.47%
Shares outstanding	43M
Short % of float	1.87%
Short % of shares	0.14%
Short ratio	0.3 days

Deeper analysis on CPHI

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this CPHI report

Is a complete CPHI research report available?

No complete published report is available for China Pharma Holdings, Inc. (CPHI) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

China Pharma Holdings, Inc. (CPHI)

Price

Financial snapshot

Fair-value bridge

Latest news · CPHI

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All CPHI indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on CPHI

Frequently asked questions